Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 20/20 | 1.00 |
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | HTR2A | P28223 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.88 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.80 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.80 |
| ▸ | CCR1 | P32246 | 1/20 | 0.80 |
| ▸ | CCR2 | P41597 | 1/20 | 0.80 |
| ▸ | CCR5 | P51681 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354921 | 1.00 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6354926 | 1.00 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6348413 | 0.98 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL18844423 | 0.98 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6347153 | 0.98 | CYP2D6 (0.97) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6348406 | 0.98 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6347150 | 0.98 | CYP2D6 (0.97) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6356481 | 0.97 | CYP2D6 (0.99) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6356490 | 0.97 | CYP2D6 (0.99) | CYP2D6CCR3DRD2SLC6A2HTR2A | |
| SCHEMBL6347997 | 0.95 | CYP2D6 (1.00) | CYP2D6CCR3DRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | CYP2D6 3121/4885CCR3 1/4885DRD2 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.